Press Releases from Novartis, a global leader in healthcare
| Source: Novartis Pharma AG
Recommended Reading
-
If approved, Cosentyx® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe1,2HS affects as many as one in 100 people worldwide,3 with more than...
Read More -
RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 241Twice as many Rhapsido-treated patients...
Read More